WHO Director-General Candidates Address Global Health Reform In First Public Campaign Event - Health Policy Watch
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Visitors register at the World Health Summit in Berlin under the banner “From Crisis to Resilience,” with over 4,000 visitors expected in person.
BERLIN – The WHO Director-General election process ignited its first public candidate conversation on Sunday (11 October) at the 2026 World Health Summit in Berlin, as four of the race’s seven declared contenders tackled the thorny question of how to make global health institutions more responsive and fit for purpose.
This article is an excerpt. To read the full content, visit the original source. Health Policy Watch
Related articles
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!